Press Releases

---------------------------------------------------------------- FOR IMMEDIATE RELEASE

CONTACTS:	César García, President and Chief Executive Officer
	818-709-1244 Ext. 123 or
	Ron Stabiner, The Wall Street Group, Inc.
	212-888-4848

IRIS INTERNATIONAL'S SAMPLE PROCESSING DIVISION SIGNS THREE-YEAR SUPPLY AGREEMENT WITH ABBOTT MOLECULAR

Covers StatSpin^® ThermoBrite™ for Abbott's FISH Product Offering

CHATSWORTH, Calif., Nov. 2, 2005 — IRIS International, Inc. (NASDAQ: IRIS) a manufacturer and marketer of automated IVD urinalysis systems and medical devices used in hospitals and reference clinical laboratories worldwide, today announced that its Sample Processing Division has entered into a three-year supply and distribution agreement with Abbott Molecular, a division of Abbott, to supply the StatSpin^® ThermoBrite™ slide denaturation/hybridization system for performing fluorescence in situ hybridization (FISH) procedures.

"We are extremely pleased to have been selected as a supplier of Abbott Molecular," stated Robert Mello, President of IRIS' Sample Processing Division, formerly StatSpin. "The ThermoBrite slide denaturation/hybridization system has been a very successful product for us since its introduction in March 2004. Hundreds of units have been placed worldwide and customers have been delighted with the quality of results that are produced."

César García, President and Chief Executive Officer of IRIS International, noted that IRIS' Sample Processing Division has always excelled in high quality products and services for clinical and veterinary laboratories. "FISH has become a mainstream technology for molecular pathology procedures performed in diagnostic laboratories and our core competencies in sample processing and small laboratory instrumentation have enabled us to enter this emerging market segment with our ThermoBrite system," he stated. "This agreement represents an important step in our strategy to broaden the Sample Processing Division's product portfolio into higher value testing markets with existing and new products."

The programmable system automates the denaturation and hybridization steps in slide-based FISH procedures, and provides walk-away convenience for clinical and research personnel.

The Company

IRIS International, Inc. (http://www.proiris.com), based in Chatsworth, Calif., is a leader in automated urinalysis technology with systems in major medical institutions throughout the world. The Company's new generation iQ^®200 Automated Urinalysis platform, utilizing image flow cytometry, patented Automated Intelligent Microscopy (AIM) technology and neural network-based particle recognition, achieves a significant reduction in the cost and time-consuming steps involved in manual microscopic analysis. The Company's StatSpin^® (www.statspin.com) subsidiary, based in Norwood, Mass., manufactures innovative centrifuges and blood analysis products. Advanced Digital Imaging Research, LLC (ADIR), (www.adires.com) based near Houston, Texas, is the Company's imaging research and development subsidiary.

SAFE HARBOR PROVISION

This news release contains forward-looking statements made in reliance upon the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, the Company's views on future commercial revenues, market growth, capital requirements, new product introductions, and are generally identified by phrases such as "thinks," "anticipates," "believes," "estimates," "expects," "intends," "plans," and similar words. Forward-looking statements are not guarantees of future performance and are inherently subject to uncertainties and other factors which could cause actual results to differ materially from the forward-looking statement. These statements are based upon, among other things, assumptions made by, and information currently available to, management, including management's own knowledge and assessment of the Company's industry, competition and capital requirements. Other factors and uncertainties that could affect the Company's forward-looking statements include, among other things, the following: the acceptance by customers of our new iQ^®200 product platform, our substantial expansion of international sales and our reliance on key suppliers, the potential need for changes in long-term strategy in response to future developments; future advances in diagnostic testing methods and procedures, as well as potential changes in government regulations and healthcare policies, both of which could adversely affect the economics of the diagnostic testing procedures automated by the Company's products; rapid technological change in the microelectronics and software industries; and increasing competition from imaging and non-imaging based in-vitro diagnostic products. The Company refers interested persons to its most recent Annual Report on Form 10-K and its other SEC filings for a description of additional uncertainties and factors that may affect forward-looking statements. The Company assumes no duty to update its forward-looking statements.